NCT02808351

Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes

Multicenter Randomized Controlled Study of Berberine for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Renal Insufficient

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 800 (actual)
• Sponsor: Nanjing First Hospital, Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The number of cardiac angiography and percutaneous coronary interventions (PCI) has increased steadily in recent years. This has resulted in the increasing incidence of contrast-induced nephropathy (CIN). Major risk factors for CIN include older age, diabetes mellitus (DM), chronic kidney disease(CKD), the concurrent use of nephrotoxic drugs, hemodynamic instability, etc. Importantly, DM appears to act as a risk multiplier, meaning that in a patient with CKD it amplifies the risk of CIAKI. The aim of this multicenter prospective, randomized, controlled study is to evaluate whether berberine treatment during and after the perioperative period would reduce the risk of CIN in a high-risk population of patients with both DM and CKD undergoing coronary angiography or noncoronary angiography, and the influence of such potential benefit on short-term outcome.

Conditions

• Diabetes Mellitus
• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	Berberine

Timeline

• Start date: 2016-07-01
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2016-06-21
• Last updated: 2022-03-29

Locations

1 site across 1 country: China